Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER3 | P43115 | 9/20 | 0.57 |
| ▸ | PTGER1 | P34995 | 7/20 | 0.57 |
| ▸ | PTGER4 | P35408 | 7/20 | 0.57 |
| ▸ | PTGER2 | P43116 | 7/20 | 0.57 |
| ▸ | EGFR | P00533 | 3/20 | 0.51 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3973206 | 0.87 | PTGER3 (0.49) | PTGER3PTGER1PTGER4PTGER2EGFR | |
| SCHEMBL3973201 | 0.85 | PTGER3 (0.47) | PTGER3PTGER1PTGER4PTGER2EGFR | |
| SCHEMBL4660476 | 0.80 | CYP2C9 (0.54) | PTGER3PTGER1PTGER4PTGER2TSHR | |
| SCHEMBL8692307 | 0.79 | CYP2D6 (0.56) | PTGER3PTGER1PTGER4PTGER2TSHR | |
| SCHEMBL10405410 | 0.77 | MEN1 (0.59) | EGFRERBB2ALDH1A1 | |
| SCHEMBL28683479 | 0.76 | MEN1 (0.51) | PTGER3PTGER1PTGER4PTGER2TSHR | |
| SCHEMBL26338441 | 0.76 | ALDH1A1 (0.52) | PTGER3PTGER1PTGER4PTGER2TSHR | |
| SCHEMBL2691075 | 0.74 | HPGD (0.64) | CYP2D6CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL7211477 | 0.74 | CYP2D6 (0.66) | TSHRCYP2D6CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL2789687 | 0.74 | GAA (0.68) | TSHRCYP2D6CYP2C9CYP2C19ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0980369-B1 | SULFONAMIDES FOR TREATMENT OF ENDOTHELIN-MEDIATED DISORDERS | ENCYSIVE PHARMACEUTICALS INC (US) | 2005-03-30 | — | — | EP | claimed |
| CN-1179961-C | Sulfonamides for the treatment of endothelin mediated diseases | ��ɪϣ����ҩ��˾ | 2004-12-15 | — | — | CN | claimed |
| CN-1130355-C | Thienyl-, Furyl-, Pyrrolyl- and biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin | TEXAS BIOTECHNOLOGY CORP (US) | 2003-12-10 | — | — | CN | claimed |
| EP-0819125-B1 | THIENYL-, FURYL-, PYRROLYL- AND BIPHENYLSULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | TEXAS BIOTECHNOLOGY CORP (US) | 2003-06-18 | — | — | EP | claimed |
| US-6458805-B2 | ANTAGONISTS; ESPECIALLY SODIUM SALTS | TEXAS BIOTECHNOLOGY CORPORATION | 2002-10-01 | — | — | US | claimed |
| US-6342610-B2 | COMPOUNDS SUCH AS N-(4-BROMO-3-METHYL-5-ISOXAZOLYL)-2-N-BENZYLBENZO(B)THIOPHENE-3-SUFONAMIDE ADMINISTERED AS ENDOTHELIN PEPTIDE RECEPTOR ANTAGONISTS | TEXAS BIOTECHNOLOGY CORP. | 2002-01-29 | — | — | US | claimed |
| US-20010039289-A1 | Formulation of sulfonamides for treatment of endothelin-mediated disorders | ENCYSIVE PHARMACEUTICALS INC. | 2001-11-08 | — | — | US | claimed |
| US-20010021714-A1 | THIENYL-, FURYL-, PYRROLYL- AND BIPHENYLSULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | ENCYSIVE PHARMACEUTICALS INC. | 2001-09-13 | — | — | US | claimed |
| WO-2001049289-A1 | PHARMACEUTICAL AND VETERINARY USES OF ENDOTHELIN ANTAGONISTS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2001-07-12 | — | — | WO | claimed |
| US-6248767-B1 | VASOCONSTRICTION | TEXAS BIOTECHNOLOGY CORP. | 2001-06-19 | — | — | US | claimed |
| CN-1253560-A | Sulfonamides for the treatment of endothelin mediated diseases | TEXA BIOTECHNOLOGY CORP (US) | 2000-05-17 | — | — | CN | claimed |
| EP-0980369-A1 | SULFONAMIDES FOR TREATMENT OF ENDOTHELIN-MEDIATED DISORDERS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2000-02-23 | — | — | EP | claimed |
| WO-1998049162-A1 | SULFONAMIDES FOR TREATMENT OF ENDOTHELIN-MEDIATED DISORDERS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1998-11-05 | — | — | WO | claimed |
| CN-1184470-A | Thienyl-, Furyl-, Pyrrolyl- and biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin | TEXAS BIOTECHNOLOGY CORP (US) | 1998-06-10 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010021714-A1 | THIENYL-, FURYL-, PYRROLYL- AND BIPHENYLSULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | EDNRA, EDNRB, NPSR1 | PTGER3 364/4885PTGER1 636/4885PTGER4 505/4885 |
| US-20010039289-A1 | Formulation of sulfonamides for treatment of endothelin-mediated disorders | EDNRA, EDNRB, ECE1 | PTGER3 261/4885PTGER1 171/4885PTGER4 334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.